Hydrocortisone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Hydrocortisone: From Corticosteroid Anti-Inflammatory Therapy to Alopecia Areata
One-Sentence Summary
Hydrocortisone is a glucocorticoid long used systemically for adrenal insufficiency replacement and topically/locally for its anti-inflammatory and immunosuppressive effects across a range of dermatological and inflammatory conditions. The TxGNN model predicts it may be effective for Alopecia Areata, with 4 clinical trials and 20 publications currently supporting this direction, including a completed Phase 3 RCT directly comparing hydrocortisone to a higher-potency steroid in this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No structured original-indication data available in this evidence pack (DrugBank original indication field empty) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L1 |
| Germany Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (DrugBank MOA field is a data gap). Based on known pharmacology, hydrocortisone belongs to the corticosteroid (glucocorticoid) class, and its efficacy as an anti-inflammatory/immunosuppressive agent across inflammatory and autoimmune skin conditions is well established in clinical practice.
For alopecia areata specifically, the mechanistic rationale is that topical corticosteroids suppress the local T-cell–mediated autoimmune attack on hair follicles — hydrocortisone is a lower-potency option within a drug class (alongside agents such as clobetasol propionate) that is already a standard dermatological treatment for this condition.
It is worth noting that this is not a truly novel repurposing signal in the traditional sense: topical hydrocortisone has long been used clinically for alopecia areata. It surfaces as a "new" prediction in this system primarily because the original indication data for this drug entry is incomplete (data gap), not because the underlying clinical use is unprecedented.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01453686 | Phase 3 | Completed | 41 | RCT in children directly comparing clobetasol propionate 0.05% cream vs hydrocortisone 1% cream for alopecia areata; addresses the lack of high-quality evidence on which topical steroid potency is preferred. |
| NCT06551818 | N/A | Not Yet Recruiting | 72 | Planned 4-arm, double-blind, placebo-controlled dose-response study of hair growth formulations in mild-to-moderate androgenic alopecia; not yet enrolling. |
| NCT04343560 | N/A | Completed | 380 | Studies abnormal steroid metabolism and its effects on bone strength/density in patients with mild autonomous cortisol secretion; indirectly relevant (steroid physiology, not alopecia treatment). |
| NCT00484679 | Phase 2 | Completed | 18 | Evaluates adrenal-axis effects of intralesional triamcinolone (a related corticosteroid, not hydrocortisone) in alopecia areata patients. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24226568 | 2014 | RCT | JAMA Dermatology | Randomized clinical trial: clobetasol propionate 0.05% vs hydrocortisone 1% for alopecia areata in children (published report of NCT01453686). |
| 36718837 | 2023 | Systematic Review/Meta-analysis | Journal of Cosmetic Dermatology | Reviews fractional laser (alone or combined) treatments for alopecia areata, contextualizing steroid and non-steroid options. |
| 28516731 | 2017 | Review | J Eur Acad Dermatol Venereol | Examines hypothalamic-pituitary-adrenal axis activity and cortisol production in alopecia areata patients. |
| 29227263 | 2017 | Review | Georgian Medical News | Discusses adaptive neuroendocrine/immune regulatory mechanisms (cortisol, insulin) in alopecia areata pathogenesis. |
| 38501938 | 2024 | Cohort/Case Series | Clinical and Experimental Dermatology | Retrospective single-centre analysis of topical corticosteroid treatment under occlusion for severe alopecia areata in children. |
| 39506493 | 2025 | Exploratory Clinical Study | Journal of Cosmetic Dermatology | Explores chronic psychological stress and cortisol/epinephrine release as triggers for alopecia areata and other dermatoses. |
| 15692503 | 2005 | Case Report | J Am Acad Dermatol | Reports 4 cases of congenital alopecia areata, including topical steroid treatment among therapies used. |
| 13368875 | 1956 | Case Series (historical) | Medical Times | Early case series on treating alopecia areata/totalis with cortisone, hydrocortisone, prednisone and prednisolone. |
| 24326563 | 2013 | Animal Study | J Investig Dermatol Symp Proc | Investigates parathyroid hormone-collagen binding domain fusion proteins as a novel alopecia areata therapy in mice (mechanistic context). |
| 13525930 | 1958 | Review (historical) | J Med Soc New Jersey | General review of alopecia areata and other common scalp problems. |
Germany Market Information
Hydrocortisone currently holds no registered market authorizations in this jurisdiction (market status: Not Marketed; 0 licenses on file). No approved indication text is available to compare against the predicted new indication.
Safety Considerations
Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-interaction data are currently available in this evidence pack (see data gap DG001: TFDA/label warnings and contraindications — flagged as Blocking for the safety pre-assessment stage).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The top-ranked prediction (alopecia areata) is supported by a completed Phase 3 RCT directly comparing hydrocortisone to an active comparator in this exact indication, plus a substantial literature base spanning decades — this is an evidence level L1 signal reflecting established clinical practice rather than a purely novel hypothesis. However, the drug currently lacks MOA data and any market authorization in this jurisdiction, and formal safety/label data are missing, so guardrails are warranted before advancing.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain official label warnings/contraindications before any S1 safety pre-assessment
- Resolve DG002: retrieve confirmed MOA data from DrugBank to strengthen the mechanistic rationale
- Confirm original approved indication(s) and licensing history for hydrocortisone in the target market
- Clarify regulatory pathway given current "Not Marketed" status before considering label extension or off-label guidance
- Lower-ranked predictions (ranks 2–10) remain at L3–L5 evidence with Hold/Research Question status and are not ready to advance without additional targeted studies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.